ASCO 2025 | Dr. Hongbing Liu: Two-Cycle Chemotherapy Plus Immunotherapy Offers New Hope for Elderly Patients with Advanced Lung Cancer

ASCO 2025 | Dr. Hongbing Liu: Two-Cycle Chemotherapy Plus Immunotherapy Offers New Hope for Elderly Patients with Advanced Lung Cancer

2025.06.25
The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, one of the world’s most influential oncology conferences, was held in Chicago from May 30 to June 3. This year, a study led by Dr. Hongbing Liu from the Second Affiliated Hospital of Nanjing Medical University, in collaboration with the Jinling Clinical Medical College team, was selected for poster presentation (Abstract #8548). The research, titled "Camrelizumab Combined with Two-Cycle Chemotherapy as First-Line Therapy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Dual-Arm, Single-Center, Phase II Study", addresses a critical clinical question: Can the duration of chemotherapy be safely reduced? The study offers important insights for personalized treatment strategies in elderly NSCLC patients. Below is an in-depth discussion with Dr. Liu on the key findings.
ASCO 2025 | Dr. Li Zhang’s OptiTROP-Lung03 Study Showcased in Oral Presentation: Sacituzumab Tirumotecan Emerges as a Breakthrough in Overcoming EGFR-Mutant NSCLC Resistance

ASCO 2025 | Dr. Li Zhang’s OptiTROP-Lung03 Study Showcased in Oral Presentation: Sacituzumab Tirumotecan Emerges as a Breakthrough in Overcoming EGFR-Mutant NSCLC Resistance

2025.06.25
Sacituzumab tirumotecan, a novel TROP2-targeting antibody-drug conjugate (ADC) developed in China, has demonstrated promising therapeutic potential across multiple tumor types, including lung and breast cancer. At the 2025 ASCO Annual Meeting, a pivotal Phase II trial—OptiTROP-Lung03, led by Dr. Li Zhang of the Sun Yat-sen University Cancer Center—was selected for an oral presentation, marking a significant step for domestically developed TROP2-ADC therapy in tackling resistance in EGFR-mutant non-small cell lung cancer (NSCLC). With this presentation, Dr. Zhang brings Chinese innovation to the global oncology stage.
ASCO 2025 | Dr. Yan Huang’s Team Reports Phase I Results of BL-B01D1, Paving a New Path in Precision Treatment for SCLC

ASCO 2025 | Dr. Yan Huang’s Team Reports Phase I Results of BL-B01D1, Paving a New Path in Precision Treatment for SCLC

2025.06.25
Small cell lung cancer (SCLC), often known as the “king of lung cancer,” has long relied on the EP regimen (cisplatin plus etoposide) as the foundation of first-line therapy for nearly three decades. Although recent years have seen the introduction of immunotherapy combined with chemotherapy, which has brought incremental survival benefits, long-term outcomes for patients remain limited. At the 2025 ASCO Annual Meeting, Dr. Yan Huang from Sun Yat-sen University Cancer Center presented the results of a Phase I study (Abstract #3002) on BL-B01D1, a bispecific antibody-drug conjugate (ADC) targeting EGFR and HER3, in patients with SCLC who had failed standard treatments. The study showed that in patients who progressed after first-line chemo-immunotherapy, BL-B01D1 achieved a median overall survival (OS) of 15.1 months and a confirmed objective response rate (ORR) of 75%—breakthrough data that may offer a potential new treatment option for this hard-to-treat disease. Oncology Frontier invited Dr. Huang to provide an in-depth interpretation of the study’s clinical significance and application prospects.
ASCO Live Update | Professor Niels van de Donk: Four Key Advantages of the Trispecific Antibody JNJ-5322 in R/R MM

ASCO Live Update | Professor Niels van de Donk: Four Key Advantages of the Trispecific Antibody JNJ-5322 in R/R MM

2025.06.24
At the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, Professor Niels van de Donk from VU University Medical Center, Amsterdam, presented the preliminary results of a first-in-human phase I study of a novel trispecific antibody (TsAb) for relapsed/refractory multiple myeloma (R/R MM) in an oral presentation (Abstract #S100). Oncology Frontier – Hematology Frontier invited Prof. van de Donk for an in-depth discussion on the study's findings and clinical implications. Highlights of the conversation are summarized below.
ASCO 2025 Expert Dialogue | Dr. Changsong Qi & Dr. Kohei Shitara: Breakthroughs with T-DXd and CAR-T Therapy Reshape the Outlook for Advanced Gastric

ASCO 2025 Expert Dialogue | Dr. Changsong Qi & Dr. Kohei Shitara: Breakthroughs with T-DXd and CAR-T Therapy Reshape the Outlook for Advanced Gastric

2025.06.20
Two pivotal studies in targeted therapy for gastric cancer drew significant attention at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The world’s first randomized controlled trial (RCT) of CAR-T therapy in solid tumors (Abstract #4003) produced positive results, demonstrating the superior efficacy and manageable safety profile of Claudin 18.2-targeted CAR-T compared to standard therapies. Meanwhile, the DESTINY-Gastric04 phase III trial (Abstract #LBA4002) comparing trastuzumab deruxtecan (T-DXd) to the current second-line standard of ramucirumab (RAM) plus paclitaxel (PTX) in HER2-positive unresectable/metastatic gastric cancer also reported encouraging efficacy and safety data. On-site, we invited the lead investigators—Dr. Changsong Qi from Beijing Cancer Hospital and Dr. Kohei Shitara from the National Cancer Center Hospital in Japan—for an in-depth conversation on the background, results, and clinical significance of these two studies.
ASCO 2025 | Dr. Wentao Fang on CheckMate 577: Adjuvant Immunotherapy Significantly Improves Survival in Non-pCR Esophageal Cancer Patients After nCRT

ASCO 2025 | Dr. Wentao Fang on CheckMate 577: Adjuvant Immunotherapy Significantly Improves Survival in Non-pCR Esophageal Cancer Patients After nCRT

2025.06.20
At the 2025 ASCO Annual Meeting, updated survival data from the CheckMate 577 trial reignited discussion within the global oncology community. The study focused on patients with esophageal or gastroesophageal junction (GEJ) cancer who had received neoadjuvant chemoradiotherapy (nCRT) followed by surgery but did not achieve a pathologic complete response (non-pCR). In this high-risk subgroup, adjuvant treatment with nivolumab demonstrated sustained disease-free survival (DFS) benefits and a numerical improvement in overall survival (OS) compared with placebo. Oncology Frontier invited Dr. Wentao Fang and Dr. Xuan Hong from Shanghai East Hospital to offer insights into the efficacy and safety data of CheckMate 577.